clinical trial · NCT04276493
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene·phase2·completed·n = 71
Breast CancerGastric CancerGastroesophageal Junction CancerZanidatamabDocetaxelTislelizumabCapecitabineOxaliplatin
brief summary
The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of zanidatamab in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and zanidatamab in combination with tislelizumab and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ) adenocarcinoma
started
Mar 23, 2020
primary completion
Dec 7, 2023
completion
Oct 31, 2024
last updated
Sep 2, 2026
official title
Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol